XML 26 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8
SHARE-BASED COMPENSATION AND EMPLOYEE BENEFIT PLANS (Tables)
12 Months Ended
Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Schedule of Stock Options Activity
A summary of stock option activity under the Plan as of December 31, 2013, and changes during the year ended December 31, 2013 are presented below: 
 
Shares
 
Weighted
Average
Exercise Price
 
Weighted-Average
Remaining
Contractual Term (in years)
Outstanding as of January 1, 2013
1,789,127

 
$
4.00

 
 
Granted
762,763

 
4.82

 
 
Exercised
(38,577
)
 
3.64

 
 
Forfeited
(208,230
)
 
4.64

 
 
Expired
(6,000
)
 
25.95

 
 
Outstanding as of December 31, 2013
2,299,083

 
$
4.16

 
8.01
Vested and exercisable as of December 31, 2013
1,167,772

 
$
4.45

 
7.36
Vested and expected to vest as of December 31, 2013
2,089,628

 
$
4.17

 
8.05
Schedule of Stock Options, Valuation Assumptions
The assumptions used to determine the value of our stock-based awards under the Black-Scholes method are summarized below:
 
 
2013
 
2012
Risk-free interest rate
0.36% - 2.7%
 
0.37% - 1.6%
Dividend yield
—%
 
—%
Expected volatility
56.5% - 67.6%
 
56.8% - 77.9%
Average expected life in years
7.0
 
5.0
Schedule of Restricted Stock and Restricted Stock Units Award Activity
A summary of restricted stock awards and deferred stock units activity under the Plan as of December 31, 2013, and changes during the year then ended are presented below: 
 
Number of
Restricted Shares and Units
 
Weighted-Average
Grant Date Fair Value
Nonvested balance as of January 1, 2013
13,656

 
$
4.08

Vested
(9,255
)
 
4.41

Forfeited
(1,067
)
 
6.58

Nonvested balance as of December 31, 2013
3,334

 
$
2.35

Schedule of Employee Stock Purchase Plan, Valuation Assumptions
The assumptions used to value the shares under the ESPP using the Black-Scholes method were as follows:
 
 
2013
 
2012
Risk-free interest rate
0.02% - 0.07%
 
0.02% - 0.10%
Dividend yield
—%
 
—%
Expected volatility
24.2% - 64.7%
 
48.9% - 93.1%
Expected life in years
3 months
 
3 months